News
Calling all income investors! Two dividend kinds deserve your attention in 2025: Colgate-Palmolive (NYSE:CL) and Emerson ...
Colgate-Palmolive posted a higher profit in the first quarter but lowered 2025 earnings guidance due to tariffs.
JP Morgan analyst Andrea Teixeira maintained Colgate-Palmolive with an Overweight rating and raised the price target from $95 ...
We look at Colgate-Palmolive Company's Q1 results, market challenges, and tariff impacts. Read to see if the CL stock is ...
The owner of skin care brand Sanex is also expecting a price hike on sold goods as a result of US President Donald Trump’s ...
Colgate-Palmolive on Friday reported better-than-expected first-quarter results and lifted its full-year sales outlook, ...
Colgate-Palmolive surpassed earnings expectations in Q1 2025, despite experiencing a decline in overall sales.
Organic sales rose 1.4% during the quarter, with pricing up 1.5% and volume down 0.1%. The impact of FX was a negative 4.4% ...
John Faucher; Chief Investor Relations Officer and Executive Vice President, M&A; Colgate-Palmolive Co Noel Wallace; Chairman of the Board, President, Chief Executive Officer; Colgate-Palmolive Co ...
April 25 (Reuters) - Colgate-Palmolive (CL.N), opens new tab reported quarterly results that beat Wall Street estimates and raised its annual sales forecast on Friday, banking on moderate price ...
Colgate-Palmolive (CL) reported $4.91 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3%. EPS of $0.91 for the same period compares to $0.86 a year ago.
Colgate-Palmolive alum Elaine Paik will step into the skincare brand’s top financial seat and will also lead the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results